Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
מצבים רפואיים
Clonal Cytopenia of Undetermined Significance
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Namrata S Chandhok, MD)Weill Cornell Medical College, New York, New York, United States
Contact: Principal Investigator (Pinkal Desai, M.D.)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Tamanna Haque, MD)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Uma M. Borate, MD, MS)Vanderbilt University Medical Center, Nashville, Tennessee, United States
Contact: Principal Investigator (Ashwin Kishtagari, MD)UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
Contact: Study coordinator (Silviya Meletath, MD, MBS) · silviya.meletath@utsouthwestern.edu · 909-560-9597Contact: Principal Investigator (Yazan Madanat, MD)
מובילי המחקר
Uma M Borate, MD, MS
Principal Investigator
Ohio State University Comprehensive Cancer Center